Skip to main content
F

Fusen Pharmaceutical Company Limited — Investor Relations & Filings

Ticker · 1652 HKEX Manufacturing
Open in API
Filings indexed 446 across all filing types
Latest filing 2025-09-29 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 1652

About Fusen Pharmaceutical Company Limited

http://www.fusenyy.com

Fusen Pharmaceutical Company Limited operates as a comprehensive pharmaceutical enterprise, integrating the cultivation of Chinese herbal medicine, drug research and development (R&D), production, and sales. The company manufactures and markets a diverse range of pharmaceutical products, including tablets, capsules, and oral solutions. Its therapeutic focus spans critical areas such as respiratory tract conditions, antiviral infections, cardio cerebrovascular diseases, digestion, and metabolism. Fusen is known for providing cold remedies, particularly those based on Shuanghuanglian, and actively develops and markets prescription drugs, demonstrating a commitment to both traditional and modern pharmaceutical solutions.

Recent filings

Filing Released Lang Actions
Interim Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled '2025 INTERIM REPORT' for Fusen Pharmaceutical Company Limited. It contains comprehensive financial sections including 'Management Discussion and Analysis', 'Consolidated Statement of Profit or Loss', 'Consolidated Statement of Financial Position', and 'Notes to the Unaudited Interim Financial Report'. It is a full interim financial report for a period shorter than a fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-29 English
DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE EQUITY INTERESTS IN HENAN FUSEN INTELLIGENT ENERGY CONSERVATION TECHNOLOGY COMPANY LIMITED
M&A Activity Classification · 1% confidence The document is a detailed Hong Kong Stock Exchange announcement by Fusen Pharmaceutical regarding a “Disclosable Transaction” under Chapter 14 of the Listing Rules, namely the conditional disposal of its entire equity interest in a subsidiary. It includes transaction terms, consideration, conditions precedent, financial effects, and Listing Rules implications. This type of corporate disposal announcement falls under M&A Activity rather than financial results, share issues, or regulatory reporting. Therefore, it is classified as an M&A Activity (Code: TAR).
2025-09-22 English
VOLUNTARY ANNOUNCEMENT "METFORMIN EMPAGLIFLOZIN TABLETS (I)" APPROVED FOR MARKETING
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement by a Hong Kong listed company regarding regulatory approval for a new pharmaceutical product. It does not contain financial results, earnings guidance, board changes, voting results, or any formal report. It is not an investor presentation or management discussion, nor a capital/financing notice. Therefore it falls under the miscellaneous regulatory announcement category.
2025-09-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Regulatory Filings Classification · 1% confidence The document is a routine monthly return filed to the Hong Kong Stock Exchange under Chapter 19B of the listing rules, detailing movements in authorized share capital, issued shares, share options, warrants, and other securities-related confirmations. It is a standardized regulatory listing return and not a standalone financial report (e.g., annual, interim), earnings release, or a specific transaction announcement. It does not announce a dividend, share buyback, or change in board or management, nor is it a presentation. Therefore it falls under the general category of Regulatory Filings (RNS).
2025-09-02 English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'Announcement of Interim Results' for Fusen Pharmaceutical Company Limited for the six months ended 30 June 2025. It contains comprehensive unaudited financial statements, including the consolidated statement of profit or loss, statement of financial position, and detailed explanatory notes. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2025
2025-08-29 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement (1,419 characters) on the Hong Kong Exchange: a Notice of Board Meeting to approve interim results and consider an interim dividend. It does not itself contain financial results nor a voting outcome, nor is it a full report or earnings release; it is a mandatory regulatory notice. This falls under the fallback category “Regulatory Filings” (RNS).
2025-08-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.